Boothbay Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

Boothbay Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,700	Closed	-$1.94M	–	2333
2025 Q4	$1.94M	Buy	+13,700	New	+$1.98M	0.03%	571
2024 Q3	–	Sell	-30,300	Closed	-$4.17M	–	1821
2024 Q2	$4.17M	Buy	+30,300	New	+$4.16M	0.1%	278
2022 Q3	–	Sell	-61,700	Closed	-$6.01M	–	2477
2022 Q2	$6.01M	Sell	61,700 -18,600	-23%	-$1.72M	0.16%	130
2022 Q1	$7.53M	Buy	80,300 +63,600	+381%	+$5.39M	0.18%	111
2021 Q4	$1.42M	Buy	+16,700	New	+$1.54M	0.03%	609
2021 Q1	–	Sell	-25	Closed	-$240K	–	1701
2020 Q4	$240K	Buy	+25	New	+$2.42K	0.01%	1029
2020 Q2	–	Sell	-76	Closed	-$658K	–	1064
2020 Q1	$658K	Buy	+76	New	+$7.44K	0.05%	402

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's NBIX Position: Q1 2026 in Review

Boothbay Fund Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 13,388 shares — an estimated $1.9M sold.

Boothbay Fund Management first reported a position in NBIX in Q4 2017 and held it in 12 quarters. The position peaked at $3.71M in Q1 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Boothbay Fund Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Boothbay Fund Management sold 13,388 Neurocrine Biosciences shares in Q1 2026, an estimated $1.9M.
Boothbay Fund Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 12 quarters.
Boothbay Fund Management's Neurocrine Biosciences position peaked at $3.71M in Q1 2023.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.